首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 製藥企業 > 全球前10大主要生物枓技企業:產業・財務・SWOT分析
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

全球前10大主要生物枓技企業:產業・財務・SWOT分析

Global Top 10 Biotechnology Companies -- Industry, Financial and SWOT Analysis

出版商 Datamonitor
出版日期 2009年07月 商品編碼 101026
內容資訊 英文 105 pages
價格
US $ 1895 PDF by E-mail (Single User License)
US $ 4738 PDF by E-mail (Global Site License)


全球前10大主要生物枓技企業:產業・財務・SWOT分析 是由出版商Datamonitor在2009年07月所出版的。 這份英文市場調查報告書包含105 pages 價格從美金1895起跳。

目錄

Abstract

Scope:

‘Top 10 Global Biotechnology Companies Report: Strategic evaluation of industry and key players' is a business report that provides a comprehensive view of the global biotechnology industry and its top 10 companies.

The report includes the following:

  • Industry analysis including market value, market volume, market share and forecast growth till 2012
  • Assessment of intensity of competition based on five-forces model including degree of rivalry, substitutes, new entrants, buyer power and supplier power
  • SWOT and 5-year financial analysis of top 10 players in the industry
  • Descriptive profiles of the leading players including the strategic initiatives undertaken by them in the last 12 months

The top 10 companies have been ascertained based on their global revenues for the financial year 2008.

Highlights:

The global biotechnology market generated total revenues of $171.8 billion in 2007, representing a compound annual growth rate (CAGR) of 10.7% for the period spanning 2003 - 07. The performance of the market is forecast to decelerate, with an anticipated CAGR of 9.9% for the five-year period 2007 - 12, which is expected to drive the market to a value of $275.8 billion by the end of 2012.

The top 10 global biotechnology companies recorded revenues of $56.7 billion during 2008, an increase of 12.6% over FY2007. The operating profit of these companies was $15.1 billion in FY2008, an increase of 12.1% over FY2007. The net profit was $10.5 billion during FY2008, an increase of 10.3% over FY2007.

The average operating margin of the top 10 companies was 17% in FY2008 as compared with that of 20.2% in FY2007. The net margin was 10.3% in 2008 as compared with that of 14.9% in 2007.

Since 2003, the global biotechnology market has witnessed a significant growth across different geographies. However, the market growth is expected to decelerate for next few years due to increased number of patent expiries and intensifying competition from biosimilars.

Reasons to Purchase

  • Gain insights into the industry, leading companies and competitors through a single report
  • Benchmark the leading players using 5-year financial analysis, ratios and adjusted financial statement data
  • Form opinions about key players using SWOT Analysis to understand internal factors (strengths and weaknesses) and external factors (opportunities and threats) influencing the companies
  • Determine industry attractiveness from five-forces analysis of constituent segments.

Table of Contents

  • Executive Summary
  • Industry analysis
  • Industry definition
  • Research highlights
  • Top 10 companies landscape
  • Market Value
  • Market Forecast
  • Market Segmentation - Product
  • Market Segmentation - Geographic
  • Five Forces Analysis
  • Summary
  • Buyer power
  • Supplier power
  • New entrants
  • Substitutes
  • Rivalry
  • Top 10 Companies Landscape
  • Revenue analysis
  • Financial performance analysis
  • Company Reports
  • Amgen
  • Genentech
  • Gilead Sciences
  • UCB
  • Genzyme
  • Biogen Idec
  • CSL
  • Celgene
  • Cephalon
  • Actelion
  • Financial Analysis
  • Amgen
  • Genentech
  • Gilead Sciences
  • UCB
  • Genzyme
  • Biogen Idec
  • CSL
  • Celgene
  • Cephalon
  • Actelion
  • Appendix

FIGURES

  • Figure 1: Global biotechnology market, $ million, 2003 - 07
  • Figure 2: Global biotechnology market forecast, $ million, 2007 - 12
  • Figure 3: Global biotechnology market segmentation - product, % share, 2007
  • Figure 4: Global biotechnology market segmentation - geography, % share, 2007
  • Figure 5: Forces driving competition in the global biotechnology market
  • Figure 6: Drivers of buyer power in the global biotechnology market
  • Figure 7: Drivers of supplier power in the global biotechnology market
  • Figure 8: Factors influencing the likelihood of new entrants in the global biotechnology market
  • Figure 9: Factors influencing the threat of substitutes in the global biotechnology market
  • Figure 10: Drivers of degree of rivalry in the global biotechnology market
  • Figure 11: Revenues of global top 10 biotechnology companies, $ million, FY2008
  • Figure 12: Revenue growth of global top 10 biotechnology companies, 2006 - 08
  • Figure 13: Operating performance analysis, FY2008
  • Figure 14: Net profit analysis, FY2008

TABLES

  • Table 1: Global biotechnology market, $ million, 2003 - 07
  • Table 2: Global biotechnology market forecast, $ million, 2007 - 12
  • Table 3: Global biotechnology market segmentation - product , % share, 2007
  • Table 4: Global biotechnology market segmentation - geography, % share, 2007
  • Table 5: Revenues of global top 10 biotechnology companies, $ million, FY2008
  • Table 6: Revenue growth of global top 10 biotechnology companies, 2006 - 08
  • Table 7: Key financials of global top 10 biotechnology companies, FY2008
  • Table 8: Key industry specific ratios, FY2008
  • Table 9: Amgen - Financial and operational highlights, 2004 - 08 ($ million)
  • Table 10: Amgen - Key industry specific ratios, 2004 - 2008
  • Table 11: Genentech - Financial and operational highlights, 2004 - 08 ($ million)
  • Table 12: Genentech - Key industry specific ratios, 2004 - 08
  • Table 13: Gilead Sciences - Financial and operational highlights, 2004 - 08 ($ million)
  • Table 14: Gilead Sciences - Key industry specific ratios, 2004 - 08
  • Table 19: UCB - Financial and operational highlights, 2004 - 08 ($ million)
  • Table 20: UCB - Key industry specific ratios, 2004 - 08
  • Table 15: Genzyme - Financial and operational highlights, 2004 - 08 ($ million)
  • Table 16: Genzyme - Key industry specific ratios, 2004 - 08
  • Table 17: Biogen Idec - Financial and operational highlights, 2004 - 08 ($ million)
  • Table 18: Biogen Idec - Key industry specific ratios, 2004 - 08
  • Table 21: CSL - Financial and operational highlights, 2004 - 08 ($ million)
  • Table 22: CSL - Key industry specific ratios, 2004 - 08
  • Table 23: Celgene - Financial and operational highlights, 2004 - 08 ($ million)
  • Table 24: Celgene - Key industry specific ratios, 2004 - 08
  • Table 25: Cephalon - Financial and operational highlights, 2004 - 2008 ($ million)
  • Table 26: Cephalon - Key industry specific ratios, 2004 - 08
  • Table 27: Actelion - Financial and operational highlights, 2004 - 08 ($ million)
  • Table 28: Actelion - Key industry specific ratios, 2004 - 08
Back to Top